In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and ...

Biogen BIIB and partner Eisai announced that the European Commission (EC) has granted marketing authorization to Leqembi ...

Eisai Europe Ltd. and Biogen Inc. announced today that the European Commission (EC) has granted Leqembi® (lecanemab) Marketing Authorisation (MA) in the European Union (EU).1 This makes the medicine ...

In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer’s disease (early AD) ...

Leqembi gains European approval after CHMP reversal, despite safety concerns tied to brain swelling and bleeding in Alzheimer ...

研究结论和讨论部分表明：该研究揭示了 AD 脑萎缩轨迹中的性别差异。女性虽海马萎缩更早、WM-hypo 负担更高，但认知衰退更慢。这可能与女性的激素水平、教育程度等因素有关。如雌激素在绝经前对女性有保护作用，绝经后减弱。低教育在女性中更普遍，却未导致女性认知衰退更快，反而在某些方面有优势。此外，不同亚型中男女神经精神症状也存在差异，如 LPA + 亚型中男性更易冷漠，MA 亚型中男性运动症状更明显 ...

The risk for amyloid-related imaging abnormalities in early-stage Alzheimer’s disease is primarily driven by the ...

Eisai and Biogen have received marketing authorisation from the European Commission (EC) for Leqembi (lecanemab) to treat Alzheimer's.

The woman’s brain was donated to research after her death, and it was analyzed by researchers for signs of Alzheimer’s ...

Quest Diagnostics has introduced a new blood test aimed at assisting physicians in confirming amyloid brain pathology related ...

The European Commission has today communicated that it has granted BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai's application for Marketing Authorization of ...